[英语新闻}，肝切除后的抗病毒治疗，提高生存 - 新的研究

StephenW

http://www.imt.ie/clinical/2011/07/post-hepatectomy-antiviral-therapy-improves-survival-%E2%80%94-new-research.html
Post-hepatectomy antiviral therapy improves survival — new research                                                                July 7, 2011  By Mary Anne Kenny Leave a Comment                                
                                       
Antiviral therapy after hepatectomy improves survival in patients with hepatitis B-related hepatocellular carcinoma, research suggests.


Overall, survival was 88 per cent after one year and 71 per cent after five years in antiviral-naïve patients who were treated with post-operative antiviral therapy, compared with 76 per cent after one year and 43 per cent after five years in those not given the treatment.
The disease-free survival rate was 66 per cent after one year and 51 per cent after five years in those in the treatment group, compared with 49 per cent after one year and 34 per cent after five years in the control group, the study of 136 patients found.
Factors that predicted long-term survival were the use of antiviral therapy, early-stage tumour size of no more than 5cm and absence of major vascular invasion.
Antiviral treatment after hepatectomy did not confer any benefit to patients with late-stage tumours or those with major vascular invasion.
There was no significant difference in the rate of tumour recurrence between the two groups, but researchers noted antiviral treatment might delay the time it takes for tumours to reoccur.
Liver function reserve in patients with antiviral treatment was not worsened at the time of tumour recurrence compared with the control group, the researchers wrote in the Archives of Surgery.
“Another potential benefit of antiviral treatment after hepatectomy is preservation of liver function reserve that would improve the chance for further surgical treatment when intrahepatic tumour recurrence has developed,” they noted.
“Antiviral therapy… should be considered after hepatectomy for HBV-related HCC, especially in early-stage tumours,” the researchers wrote.
Archives of Surgery 2011; 146:675-681.
               




(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

[肝切除术后的抗病毒治疗，提高生存与B型肝炎相关的肝癌患者，研究表明。

总体而言，生存期为一年后5年，在抗病毒初治治疗的患者手术后的抗病毒治疗后71％的88％相比，一年后76％和43％后，5年在那些不接受治疗。

无病生存率为66％一年后，51％，五年后，在治疗组相比，一年后的49％和34％，在对照组的5年后，研究136例患者发现。

预测长期生存的因素，使用抗病毒药物治疗，早期肿瘤大小不超过5cm，并没有大血管的入侵。

肝切除术后的抗病毒治疗并没有赋予任何与晚期肿瘤或与大血管的入侵的患者受益。

在两组之间的肿瘤复发率没有显着差异，但研究人员指出，抗病毒药物治疗可能延缓肿瘤再次发生所需要的时间。

抗病毒治疗患者的肝功能储备是不是在恶化，肿瘤复发的时间，与对照组相比，研究人员写道，在手术的档案。

“肝切除术后的抗病毒治疗的另一个潜在的好处是保护肝功能储备，以改善为进一步手术治疗肝内肿瘤复发时，已开发的机会，”他们指出。

“抗病毒治疗......应考虑为乙型肝炎病毒有关的肝癌肝切除后，特别是在早期肿瘤，”研究人员写道。

2011年外科档案;146:675-681。